Open-Label Nonrandomized Phase IB Study to Characterize the Safety and Recommended Dose of Tinostamustine in Combination with Nivolumab in Patients with Advanced Melanoma (ENIgMA).

Oct 15, 2025 |

Accessibility Adjustments

Accessibility Commitment for Knoa Pharma LLC

At Knoa Pharma, we are committed to making our digital presence as accessible and inclusive as reasonably possible for all users, including individuals with disabilities. Our goal is to improve the usability of https://www.knoapharma.com and to support a more accessible experience for everyone, regardless of their abilities or the technologies they use.

Our Approach to Accessibility

We aim to align with the Web Content Accessibility Guidelines (WCAG), which define internationally recognized standards for digital accessibility. While full compliance cannot always be guaranteed, we strive to implement improvements where feasible and regularly review accessibility-related aspects of our website. Accessibility is an ongoing process, and we are committed to improving the experience over time as technologies, standards, and user needs evolve.

Accessibility Features

To support accessibility, https://www.knoapharma.com may utilize tools such as the OneTap accessibility toolbar. This interface provides users with a range of helpful features, including:

Adjustable text size and contrast settings
Highlighting of links and text for better visibility
Full keyboard navigation of the toolbar interface
Quick launch via keyboard shortcut: Alt + . (Windows) or ⌘ + . (Mac)

Please note the following:

The availability and effectiveness of these features depend on the website's configuration and ongoing maintenance.
While we strive to ensure accessibility, we cannot guarantee that every part of https://www.knoapharma.com will be fully accessible at all times. Some content may be provided by third parties or affected by technical constraints beyond our immediate control.

Feedback and Contact

We welcome your feedback. If you experience any accessibility barriers or have suggestions for improvement, please contact us. We are committed to reviewing all inquiries and aim to respond within 3–5 business days. If you require assistance accessing any part of this website, we are happy to provide support through alternative channels upon request. Last updated: May 1, 2026

Select your accessibility profile

Vision Impaired Mode

Enhances website's visuals

Seizure Safe Profile

Clear flashes & reduces color

ADHD Friendly Mode

Focused browsing, distraction-free

Blindness Mode

Reduces distractions, improves focus

Epilepsy Safe Mode

Dims colors and stops blinking

Content Modules

Font Size

Default

Line Height

Default

Color Modules

Orientation Modules

Open-Label Nonrandomized Phase IB Study to Characterize the Safety and Recommended Dose of Tinostamustine in Combination with Nivolumab in Patients with Advanced Melanoma (ENIgMA).

About Us

Patient-Focused

Healthcare
Professionals

Public Health Initiatives

News

Legal

Open-Label Nonrandomized Phase IB Study to Characterize the Safety and Recommended Dose of Tinostamustine in Combination with Nivolumab in Patients with Advanced Melanoma (ENIgMA).

About Us

Patient-Focused

HealthcareProfessionals

Public Health Initiatives

News

Legal

Privacy Policy Updates

Healthcare
Professionals